Trovafloxacin: a new fluoroquinolone (Q37879173)

24 August 2017

1 reference

title

Trovafloxacin: a new fluoroquinolone (English)

1 reference

24 August 2017

A A Alghasham

1

1 reference

24 August 2017

M C Nahata

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

Annals of Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

33

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

48-60

1 reference

In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone

24 August 2017

cites work

1 reference

The chemistry and biological profile of trovafloxacin

21 January 2018

1 reference

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

21 January 2018

1 reference

Oral bioavailability of trovafloxacin with and without food in healthy volunteers

21 January 2018

1 reference

Fluoroquinolone antimicrobial agents

21 January 2018

1 reference

Bactericidal activity of trovafloxacin (CP-99,219).

21 January 2018

1 reference

The mode of action of quinolones: The paradox in activity of low and high concentrations and activity in the anaerobic environment

21 January 2018

1 reference

Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers

21 January 2018

1 reference

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers

21 January 2018

1 reference

Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy

21 January 2018

1 reference

In vitro extracellular and intracellular activity of two newer and two earlier fluoroquinolones againstListeria monocytogenes

21 January 2018

1 reference

In vitro activity of the new fluoroquinolone CP-99,219.

21 January 2018

1 reference

The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents

21 January 2018

1 reference

The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.

21 January 2018

1 reference

In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin

21 January 2018

1 reference

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria

21 January 2018

1 reference

In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

21 January 2018

1 reference

In vitro activity of sparfloxacin

21 January 2018

1 reference

In vitro activity of AT-4140 against clinical bacterial isolates

21 January 2018

1 reference

In vitro activity of sparfloxacin compared with those of five other quinolones

21 January 2018

1 reference

Antimicrobial activity of DV-7751a, a new fluoroquinolone

21 January 2018

1 reference

Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes

21 January 2018

1 reference

Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media

21 January 2018

1 reference

Susceptibility of Chlamydia trachomatis to trovafloxacin

21 January 2018

1 reference

Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens

21 January 2018

1 reference

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis

21 January 2018

1 reference

Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis

21 January 2018

1 reference

Safety and efficacy of ciprofloxacin in paediatric patients--review

21 January 2018

1 reference

Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation

21 January 2018

1 reference

Quinolone antimicrobial agents and theophylline

21 January 2018

1 reference

Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin

21 January 2018

1 reference

In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin

21 January 2018

1 reference

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin

21 January 2018

1 reference

Prostatic tissue levels of ofloxacin

21 January 2018

1 reference

Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci

21 January 2018

1 reference

In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone

21 January 2018

1 reference

Antibacterial activity of trovafloxacin against gram-positive blood culture isolates from nosocomial infections

21 January 2018

1 reference

In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin

21 January 2018

1 reference

In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia

21 January 2018

1 reference

In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae

21 January 2018

1 reference

In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens

21 January 2018

1 reference

In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates

21 January 2018

1 reference

Activity of trovafloxacin against blood isolates of Streptococcus pneumoniae in Sweden

21 January 2018

1 reference

In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram- positive and gram-negative pathogens from respiratory tract infections

21 January 2018

1 reference

Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology

21 January 2018

1 reference

In-vitro activity of trovafloxacin (CP99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates

21 January 2018

1 reference

In-vitro activity of a new quinolone (CP-99,219) compared with ciprofloxacin, pefloxacin, azithromycin and penicillin against Neisseria gonorrhoeae

21 January 2018

1 reference

Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes

21 January 2018

1 reference

The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria

21 January 2018

1 reference

Methods of measuring susceptibility of anaerobic bacteria to trovafloxacin, including quality control parameters

21 January 2018

1 reference

Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation

21 January 2018

1 reference

Postantibiotic effect of trovafloxacin on Pseudomonas aeruginosa

21 January 2018

1 reference

A study of the phototoxic potential of trovafloxacin in BALB/c mice

21 January 2018

1 reference

Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin

21 January 2018

1 reference

Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals

21 January 2018

1 reference

Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission.

21 January 2018

1 reference

Effect of Maalox and omeprazole on the bioavailability of trovafloxacin

21 January 2018

1 reference

Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers

21 January 2018

1 reference

Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.17460

1 reference

24 August 2017

1 reference